Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shoulder InnovationsFRA:VB3 -1.89%12 Cash-to-Debt is 6.67 as of Jun. 2026, which is 43% above its 10-year median of 4.67. GuruFocus rates FRA:VB3 with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Shoulder Innovations ranks better than 70.43% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Shoulder Innovations's cash to debt ratio for the quarter that ended in Jun. 2026 was 6.67.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Shoulder Innovationscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Shoulder Innovations's Cash-to-Debt or its related term are showing as below:
FRA:VB3'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.02 Med: 4.67 Max: 9.2
Current: 6.67
During the past 3 years, Shoulder Innovations's highest Cash to Debt Ratio was 9.20. The lowest was 1.02. And the median was 4.67.
FRA:VB3's Cash-to-Debt is ranked better than 70.43% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs FRA:VB3: 6.67
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Shoulder Innovations Cash-to-Debt Related Terms
Shoulder Innovations Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Shoulder Innovations's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:VB3 vs MASS, PACB, SGHT: Cash-to-Debt Comparison
For the Medical Devices subindustry, Shoulder Innovations's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shoulder Innovations Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shoulder Innovations's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Shoulder Innovations's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shoulder Innovations (FRA:VB3) has a Cash-to-Debt of 6.67 as of Jun. 2026. This is 43% above median its historical median of 4.67. Over the past decade, Shoulder Innovations' Cash-to-Debt has ranged from 1.02 to 9.20. According to the industry distribution chart, Shoulder Innovations ranks #249 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 29.6%.
Is Shoulder Innovations' Cash-to-Debt too high?
Shoulder Innovations' current Cash-to-Debt of 6.67 is 43% above median its 10-year median of 4.67. Over the past 10 years, this metric has ranged from a low of 1.02 to a high of 9.20. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Shoulder Innovations' value of 6.67 is 308% above this industry median. Based on the distribution chart, Shoulder Innovations ranks #249 out of 842 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shoulder Innovations has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Shoulder Innovations' Cash-to-Debt compare to MASS and PACB?
According to the Medical Devices & Instruments industry distribution chart, Shoulder Innovations ranks #249 out of 842 companies for Cash-to-Debt. This puts Shoulder Innovations in the upper half of its industry. The industry median Cash-to-Debt is 1.64. Shoulder Innovations' value of 6.67 is 308% above this benchmark. Historically, Shoulder Innovations' own Cash-to-Debt has ranged from 1.02 to 9.20 over the past decade. While the company's 10-year median is 4.67 vs. the industry median of 1.64, Shoulder Innovations has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shoulder Innovations's current Cash-to-Debt of 6.67 is 308% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shoulder Innovations's current Cash-to-Debt is 6.67, which is 43% above median its own 10-year median of 4.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shoulder Innovations stock overvalued right now?
Shoulder Innovations (FRA:VB3) has a current Cash-to-Debt of 6.67. The current Cash-to-Debt is 6.67, which is 43% above median its 10-year median of 4.67 and 308% above the Medical Devices & Instruments industry median of 1.64. Shoulder Innovations' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Shoulder Innovations (FRA:VB3), the current Cash-to-Debt is 6.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System. Geographically, the company operates in United States and are planning to expand.
12GF Score
Get the complete analysis for FRA:VB3
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB3 has been successfully added to your 
